Mohamad Sandid, MD
Nephrology · Wichita, KSNPI 1992778518
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,736 of the $6,184 with a category attached, or 76.6%. 32 manufacturers reported payments, led by AstraZeneca at 28.7% of the total. Reporting peaked in 2024 at $2,819 and has fallen 68.1% since, to $900 in 2025.
Across 206 payments — averaging $30.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$580
- Calliditas Therapeutics US Inc.$517
- Bayer$389
- Novo Nordisk$314
- Mallinckrodt Hospital Products Inc.$273
- plus $2K from 26 others
Across 1 payment — averaging $1624.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$2K
What the payments were for
- Travel & lodging$1,18819%
- Food & beverage$4,73677%
- Education$2604%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $1,776 |
| Amgen(2 entities) | 16 | $580 |
| Calliditas Therapeutics US Inc. | 22 | $517 |
| Bayer | 14 | $389 |
| Novo Nordisk | 10 | $314 |
| Mallinckrodt Hospital Products Inc. | 10 | $273 |
| Akebia Therapeutics Inc | 13 | $251 |
| Boehringer Ingelheim | 11 | $219 |
| OPKO Pharmaceuticals, LLC | 12 | $186 |
| Vifor Pharma, Inc. | 9 | $163 |
| Novartis | 7 | $161 |
| Fresenius USA Marketing, Inc. | 10 | $156 |
| Mallinckrodt Enterprises LLC | 3 | $130 |
| Recor Medical Inc | 2 | $130 |
| AbbVie | 2 | $128 |
| Ardelyx, Inc. | 6 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $103 |
| GSK | 4 | $85 |
| Kyowa Kirin, Inc. | 4 | $75 |
| Aurinia Pharma U.S., Inc. | 4 | $72 |
| ANI Pharmaceuticals, Inc. | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Sanofi | 2 | $40 |
| Apellis Pharmaceuticals, Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 3 | $37 |
| Travere Therapeutics, Inc. | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Nxstage Medical, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$343
- TEFLARO$124
- Ozempic$121
- PARADISE RENAL DENERVATION SYSTEM$110
How this compares
$6,184 in reported general payments places this provider in the 75th percentile of 55 nephrology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 358 | $252,365 |
| FarxigaDapagliflozin Propanediol | 300 | $230,457 |
| AuryxiaFerric Citrate | 21 | $31,970 |
| KerendiaFinerenone | 31 | $22,857 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $18,980 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $9,963 |
| DapagliflozinDapagliflozin Propanediol | 15 | $8,291 |
| Bumetanide | 196 | $7,240 |
| Cinacalcet Hcl | 16 | $4,202 |
| Potassium Chloride | 168 | $3,057 |
| Mycophenolate Mofetil | 27 | $2,191 |
| Midodrine Hcl | 36 | $1,774 |
| Sevelamer Carbonate | 20 | $1,748 |
| Metolazone | 89 | $1,725 |
| Lisinopril | 237 | $1,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $219 | $252,365358 claims |
| AstraZenecaFarxiga, Lokelma | $1,776 | $240,420312 claims |
| Akebia Therapeutics IncAuryxia | $251 | $31,97021 claims |
| BayerKerendia | $389 | $22,85731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 55 nephrology providers in Kansas.
Other nephrology in Wichita
- Edgard WehbeWichita$49K
- Dennis RossWichita$12K
- Jany MoussaWichita$4K
- Amanda ValliantWichita$3K
- Ushasri ChallaWichita$3K
- Joseph MeouchyWichita$2K
- Michael GrantWichita$2K
- Lisa WeberWichita$2K
- Levi ShortWichita$1K
- Kenneth KovachWichita$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.